Abstract
Most SARS-CoV-2 infected patients experience influenza-like symptoms of low or moderate severity. But, already in 2020 early during the pandemic it became obvious that many patients had a high incidence of thrombotic complications, which prompted treatment with high doses of low-molecular-weight heparin (LMWH; typically 150-300IU/kg) to prevent thrombosis. In some patients, the disease aggravated after approximately 10 days and turned into a full-blown acute respiratory distress syndrome (ARDS)-like pulmonary inflammation with endothelialitis, thrombosis and vascular angiogenesis, which often lead to intensive care treatment with ventilator support. This stage of the disease is characterized by dysregulation of cytokines and chemokines, in particular with high IL-6 levels, and also by reduced oxygen saturation, high risk of thrombosis, and signs of severe pulmonary damage with ground glass opacities. The direct link between SARS-CoV-2 and the COVID-19-associated lung injury is not clear. Indirect evidence speaks in favor of a thromboinflammatory reaction, which may be initiated by the virus itself and by infected damaged and/or apoptotic cells. We and others have demonstrated that life-threatening COVID-19 ARDS is associated with a strong activation of the intravascular innate immune system (IIIS). In support of this notion is that activation of the complement and kallikrein/kinin (KK) systems predict survival, the necessity for usage of mechanical ventilation, acute kidney injury and, in the case of MBL, also coagulation system activation with thromboembolism. The general properties of the IIIS can easily be translated into mechanisms of COVID-19 pathophysiology. The prognostic value of complement and KKsystem biomarkers demonstrate that pharmaceuticals, which are licensed or have passed the phase I trial stage are promising candidate drugs for treatment of COVID-19. Examples of such compounds include complement inhibitors AMY-101 and eculizumab (targeting C3 and C5, respectively) as well as kallikrein inhibitors ecallantide and lanadelumab and the bradykinin receptor (BKR) 2 antagonist icatibant. In this conceptual review we discuss the activation, crosstalk and the therapeutic options that are available for regulation of the IIIS.
Introduction
COVID-19 has been shown to have a multifaceted effect on the immune system. In a recently published article, we reported that the innate immune system of the blood, here designated the intravascular innate immune system (IIIS), is strongly activated in severe COVID-19 with ARDS (), which is the major explanation for the serious course of the disease. In this article we review the IIIS and how its physiological function contributes to tissue injury and to the proinflammatory state during severe COVID-19. Finally, we review potential treatment targets within the IIIS with existing drugs that could be expected to modulate the disease course in COVID-19.
The Intravascular Innate Immune System (IIIS)
The blood contains a large number of plasma proteins and cells that constitute our innate barrier both in terms of recognition and elimination of microorganisms. Here, we define the IIIS and focus on the network of proteins and cells that forms the innate immune system in blood leading to thromboinflammation (). The IIIS consists of the cascade system of the blood: the complement system, the coagulation system, the kallikrein/kinin (KK; or contact system), and the fibrinolytic system. Also, individual proteins related to the cascade systems such as collectins, pentraxins, etc. belong to the IIIS, as do blood cells, e.g., granulocytes, monocytes, platelets and endothelial cells. These proteins are also available in the mucous membranes of the body, especially during inflammation either by passive diffusion or by active synthesis in the lining epithelial cells, while cells, such as granulocytes and monocytes, are recruited by chemotaxis mediated by the anaphylatoxins (C3a, C5a), by bradykinin (BK) and by chemokines.
Over the years, IIIS research has been very separated, not only in the laboratory but also in the collaboration between researchers and in the literature. For obvious reasons, human blood samples have been used for the studies in the various disciplines of the IIIS, and since the blood needs to be anticoagulated to be separated into a fluid phase and blood cells, different anticoagulants have been used. Divalent cations are necessary for IIIS function: the coagulation cascade requires Ca2+ and the complement cascade both Ca2+ and Mg2+ ions, which affects the usage of anticoagulant for the different cascade system. As a consequence, EDTA (chelating both Ca2+ and Mg2+) is used for assessment of complement activation fragments/products in plasma, while the corresponding anticoagulant for the coagulation, contact and fibrinolytic systems is citrate (chelating Ca2+ ions, but not Mg2+). Studies of the complement system function is performed using serum (i.e., the remaining fluid-phase after blood is coagulated), whereas for the coagulation, KK, and fibrinolysis systems, citrate reconstituted with Ca2+ ions is the plasma preparation of choice. These pre-analytic procedures have totally separated the research disciplines. Further aggravating the problem, cell studies have in many cases been performed on heparin blood, where activation of the coagulation and complement systems are considerably dampened by the high concentrations of heparin. Consequently, there is no generally used holistic assay format available for simultaneous assessment of all IIIS functions. However, for specialized in vitro studies heparin-coated tubes or tubing can be used, leaving the blood fresh and unaffected (). In this conceptual review the intension is to consider these components of the blood as an intact network that gives rise to an integrated innate immune response in late-stage COVID-19. The findings by us and others support this approach.
Organization of the IIIS
The schematic structure of the IIIS is described in Figure 1, which focuses on the interaction of the cascade systems of the blood, i.e., the complement, coagulation, KK and fibrinolytic systems. The reason for highlighting the cascade systems is that they contain most of the recognition molecules that specifically target DAMPs and PAMPs and trigger activation of the entire IIIS. In the figure, they are marked as components of the activation pathways that they initiate. The complement system has three defined activation pathways: the classical (CP), the lectin pathways (LP) and the alternative (AP) that are triggered by different stimuli ().
The CP is initiated by C1q, which binds to negatively charged surfaces, to IgG and IgM in immune complexes, and to target-bound pentraxins such as CRP and pentraxin 3.
The LP is activated by a number of lectins (i.e., carbohydrate-binding proteins) such as MBL, Ficolin-1, -2, and -3, and by the Collectins 10/11 ().
The AP functions primarily as an amplification loop but can be specifically regulated by properdin in concert with C3 and by factor H as an important recognition molecule controlling the AP convertase.
Figure 1
In vivo, the coagulation system is mainly activated by the extrinsic pathway elicited by tissue factor (TF), which is exposed in the vessel wall after endothelial cell damage. TF is also expressed by multiple cells in response to inflammatory signals () and when cell-bound TF is exposed to blood it leads to a strong coagulation activation. Active TF can also be expressed by activated monocytes in response to, e.g., C5a and on the endothelium during inflammation. The KK system is an alternative route for coagulation activation, initiated on contact between blood and negatively charged foreign surfaces. Activation of the contact system is the reason why blood collected without an anticoagulant, coagulates in a test tube. KK is also regulating the vascular permeability on endothelial cells ().
Factor XII (FXII) has a dual role in that it is the starting point of both the intrinsic pathway activation of the coagulation system and KK system. FXII probably has a limited role in physiological hemostasis, which is illustrated by the fact that FXII deficiency (Hageman disease) does not lead to an increased tendency for bleeding (). In contrast, inhibition of FXII is considered as a new possible strategy as an antithrombotic drug with minor risk for bleeding (). The KK system consists of FXII, prekallikrein and high molecular weight kininogen (HMWK) (). FXIIa cleaves prekallikrein generating kallikrein. Kallikrein can cleave FXII and prekallikrein thereby providing a positive feedback loop. The KK system elicits inflammation via kallikrein, which cleaves HMWK generating BK.
The fibrinolytic system is initiated by urokinase, tissue plasminogen activator (tPA) and FXIIa by activating plasminogen to plasmin (). Activated plasmin in turn breaks down the fibrin network formed in the final stages of the coagulation reaction, and thus acts as a physiological restriction mechanism that limits the propagation of the clot ().
The Function of the IIIS
Significant cross-activation can take place directly or indirectly via leukocytes and platelets, which means that activation of one of the cascade systems can spread to the entire IIIS. The physiological end result of IIIS activation is thromboinflammation, which stops bleeding by sealing blood vessel leakage through fibrin formation and platelet aggregation, and supports the clearance of damaged cells by attracting leukocytes that remove the damaged tissue. The IIIS is the start of wound healing after an injury, where the “waste management function”, i.e., removal of foreign substances, particles and apoptotic or necrotic cells is an important task. This process is combined with the release of growth factors from, e.g., activated platelets, which ultimately leads to tissue healing and scar formation ().
In a similar way, the IIIS reacts to infections caused by different types of microorganisms. In these reactions, the IIIS helps to kill and remove the microorganisms or the infected cells, after which the tissue is cleansed and healed as a result of IIIS functions. Sometimes, however, the reaction can shoot over the target and become too strong, which leads to severe inflammation and tissue damage. The end result is an excessive and pathological thromboinflammation with activation of all IIIS components such as in sepsis (Figure 1).
COVID-19 and IIIS Activation Leading to Thrombinflammation
The COVID-19 pandemic, which is caused by the corona virus SARS-CoV-2 was initially described in Wuhan, China at the end of 2019 and has since had an immense effect on human society worldwide. Most SARS-CoV-2 infected patients experience influenza-like symptoms of low or moderate severity that are characterized by sore throat, fever, a dry cough, intestinal problems, and a loss of taste and smell. Early in the pandemic, it was reported that most patients suffered from an acute-phase reaction, with high levels of certain plasma proteins, e.g., fibrinogen, C3, and ferritin that were sometimes multiple times higher than normal (). It also became clear that there was an increased risk of severe thromboembolism (, ). In some patients, the disease aggravated after approximately 9 to 10 days and turned into a full-blown ARDS-like pulmonary inflammation with endothelialitis, thrombosis and vascular angiogenesis, which often required intensive care treatment with ventilator support (). The lung injury in COVID-19 resembles the pulmonary complications that have been observed in earlier SARS-1 and MERS epidemics (). In the beginning of the COVID pandemic, up to 30% of the intensive care unit (ICU) patients died due to pulmonary and other organ dysfunctions. Those patients who reached the late-stage syndrome developed a severe pulmonary inflammation with general cyto-/chemokine expression (), reduced oxygen saturation, increased risk of pulmonary thrombosis, and signs of severe pulmonary damage revealed by CT, particularly in the periphery of the lungs (, ).
In 2020, we studied the first 65 patients with intensive care-requiring COVID-19 admitted to the ICU of the university hospital in Uppsala, Sweden (). These patients were admitted to the ICU before the therapeutic procedures now used, such as corticosteroids, were introduced. These patients were comprehensively investigated and were found to have a pronounced activation of the IIIS, with activation of all cascade systems and especially the KK system with prekallikrein, FXII and HMWK consumption (i.e. activated) and kallikrein/C1-INH complex formation ().
Thromboinflammatory Changes in Various Tissues of COVID-19 Patients
In COVID-19 patients, all parts of the IIIS are strongly activated, especially in those who are admitted to the ICU with ARDS-like symptoms. Most morphological studies have been performed on lung tissue from autopsies of patients that had succumbed at the ICU, e.g. (, ). Macroscopic observations show that large sections of the pulmonary lobes were clogged with cells and fluid, explaining the poor oxygenation of the blood in severely ill patients. From these cases of seriously ill COVD-19 patients, it was observed that the pulmonary tissue was infiltrated with immune cells (). Initially, lymphocytes and macrophages were reported to be the dominating cell types (), but later studies also showed that PMNs were important players (). This discrepancy was probably due to that the latter observation were obtained in patients with earlier disease. Another important finding is that the alveolar space is filled with plasma proteins, e.g., fibrinogen giving rise to fibrin clots and that the interalveolar capillaries are activated and obstructed with platelet-containing thrombi (Figure 2). A few cases with immunohistochemical studies of complement components have been performed (, ). They show deposition of C4d, C3d, factor B, sC5b-9 on the endothelium in various tissues, preferentially in the lung, which can be interpreted as if complement activation via the CP or/and the LP occurs with amplification via the AP. Taken together these findings are consistent with a widespread thromboinflammation in the lungs.
Figure 2
Late-stage severe COVID-19 primarily affects the lungs but extends to other organs causing, in the more serious cases, multiorgan impact including cardiac, central nervous system and kidney injury (–). Myocardial dysfunction, arrhythmia and acute coronary syndrome have been reported in association with COVID-19, but in a recently performed study on 30 patients with severe COVID-19 disease late cardiac pathology of biopsies showed no relevant cardiac histopathological alterations (, ). At present the contribution of SARS-CoV2 on cardiac lesions remains to be established (). Activation of the complement system might be involved in the worsening of renal symptoms since deposition of C3 was significant in renal arteries and in glomerular capillaries of COVID-19 biopsies (). This is supported by findings in our own study, which shows a correlation between C3a generation and glomerular filtration rate (). Neurological disorders associated with COVID-19, such as outright encephalitis is rare but has been reported with direct SARS-CoV2 detection in brain tissue (). However, severe COVID-19 with long ICU stay has been associated with critical illness involving neuro/myopathy () and post intensive care syndrome () where thromboinflammation may play a role.
Thrombosis in COVID-19
Already early in the COVID-19 pandemic, it appeared that moderately to seriously ill patients showed a very strong involvement of the coagulation system, and a high incidence of thromboembolic complications was reported on both the arterial and the venous side. In order to prevent these complications, treatment of the patients with high doses (typically 150-300 IU/kg) of LMWH was used (, ). Initially it was thought that the cause of the thromboembolism was an effect directly targeting the coagulation system but there was no real evidence of a systemic activation. Morphological data from the lungs showed that defined sections of the tissue were rich in microcapillary thrombi suggesting rather that the clotting process was taking place locally close to the activated endothelium (). The coagulation abnormalities that occur during COVID -19 disease were given a special name, COVID -19-associated coagulopathy (CAC), to emphasize what has emerged over time, that it is a condition with certain characteristics of its own. It is clear that CAC differs from the picture seen in sepsis and the so-called DIC (disseminated intravascular coagulation) where low platelet counts are a typical sign and extensive consumption of platelets and coagulation factors leads to thrombosis and bleeding at the same time (, ). Severely ill COVID -19 patients instead have normal or high platelet levels and are characterized by greatly elevated plasma levels of the fibrin degradation product D-dimer, which is a sensitive marker of fibrinolysis and coagulation turnover and probably reflects widespread thrombosis in e.g. small vessels in the lungs. It has been possible to reproduce the CAC phenotype in a primate model infected with SARS-CoV-2, and where an extensive fibrin deposition in the lung tissue was observed, in line with findings from autopsy materials of deceased COVID -19 patients (, ).
A number of hypotheses regarding the mechanisms behind CAC have been proposed. We have studied the relationship between complement and CAC, and shown that thrombosis in intensive care COVID -19 patients is linked to high activity in the LP and high plasma levels of the LP protein MBL (). Future studies may show whether there is an underlying causal relationship between the LP and thrombosis, something that is supported by preclinical results where LP components MASP-1 and MASP-2 have a coagulation factor-like activity and can directly activate fibrinogen and prothrombin in in vitro experiments (). There are also reports that neutrophil extracellular traps (NETs) that are released in response to C5a may be an initiator of coagulation since NETs expose TF and bind FXII (). Similarly, activated endothelial cells express TF, which may contribute to the thromboinflammation.
Activation Individual Components of IIIS in COVID-19
In COVID-19 an acute phase reaction increases the concentration of a number of plasma proteins multi-fold and thereby facilitates IIIS activation (). Multiple proinflammatory cytokines and chemokines such as TNF, IL-1β, IL-6, and MCP-1 are produced in response to C3a and C5a generation that further amplifies the production of acute-phase proteins (, ). The IIIS activation is multifactorial: The virus itself can activate the IIIS directly via the CP and LP of the complement system and via the KK system (–). Another likely activation mechanism is tissue damage in the lungs with apoptotic and necrotic cells that initiates the overactivation of IIIS in its function to eliminate cells or cell debris ().
The Complement System
The complement system was early suspected to be involved in the pathophysiology of severe COVID-19 disease (, –) and has thereafter been thoroughly investigated and shown to be involved in the disease and correlated with the severity of the disease. The first indication was reported early in the pandemic where increased levels of sC5b-9 were detected and a bit later a more complete report was published; both demonstrating that increased levels of sC5b-9 were associated with severe disease (, ). Thereafter, several comprehensive studies have been published, which assess a number of different complement parameters. These studies show that individual complement components increase and decrease in concentration during the course of the disease without any clear patterns (, ). For instance, C3 and C4 and other components such as C1q and MBL, and complement function (CP and AP) are elevated in some patients and decreased in others, indicating that both overexpression and complement activation with consumption occur. Overexpressed and elevated levels of factor B tend to be associated with severe COVID-19. In addition to sC5b-9 generation, formation of other activation markers occurs: C4d, Bb, C3a, and C3d,g are generated and seem to be activated early in the disease. The early trigger of complement activation is still unclear; most likely several activators elicit this response. Activation has been reported to be mediated by the intact virus via intracellular complement activation () but also by virus proteins expressed on the surface of infected cells. The virus itself has been shown to bind MBL, Ficolin-2 and Collectin-11, via its S- and N-proteins, with subsequent LP-mediated C3b and C4b deposition (, ). Structural parts of the virus have also been shown to bind C1q and trigger complement activation (). COVID-19 is strongly associated with ischemic cells, apoptosis, and cell death (, , ), initially occurring in the lung tissue. These conditions lead to binding of MBL, MASP-2 and C1q to the cells (see below), which may be the combined initiators of the accelerating complement activation that occurs particularly in severely ill patients. In our own study, the C1q concentration is low (consumed) in several patients at admission to the ICU approximately at day 10, possibly caused by damaged cells in the lungs ().
The combined data indicate that the maximum activation occurs at approximately day 10 coinciding with when patients are most likely to be admitted to the ICU. C4 and C3 consumption combined with C4d, C3a and C3d,g generation supports complement activation via CP/LP activation. Daily monitoring of C3d,g has been reported to predict outcome in patients hospitalized with COVID-19 in combination with SARS-CoV-2 nucleocapsid antigen, RNA in blood, IL-6, and CRP ().
The KK System
In several early reviews and in vitro studies, the KK system was suggested to participate in the thromboinflammation of COVID-19 (, –), without presenting any evidence of KK system activation in vivo. No direct evidence of such activation was published until reports from us, and Busch et al. showed strong KK system activation in severely ill ICU patients (, ). The KK system activation was assessed by consumption of prekallikrein, HMWK and FXII, and by increased levels of kallikrein/C1-INH complexes (). The activation of prekallikrein and HMWK on the admission to the ICU was shown to have prognostic significance for survival and the need for mechanical ventilation, but also for other systemic and specific organ parameters, such as, poor kidney function.
The Fibrinolytic System
A consequence of the ongoing coagulation activation is generation of fibrin from fibrinogen. In the clot that is formed, plasmin is generated, which cleaves fibrin into fragments including D-dimer. D-dimer is an important clinical biomarker for fibrinolysis and indirectly for clot formation. Due to its general availability, this marker was one of the first biomarkers of IIIS reported to increase in COVID-19 and the levels were found to be associated with disease severity ().
Granulocytes (PMN)
The neutrophilic granulocytes, which are found in the lungs early in the course of the disease (),have a profound effect on the outcome of COVID-19 (). Several drivers of cell infiltration exist and the anaphylatoxins of the IIIS (C3a and C5a) as well as BK are likely to be important contributors. Chemotactic effects are mediated by the specific receptors C3aR (C3a), C5aR1 and 2 (C5a) and by BKR1 and 2 (BK). These receptors also trigger activation of the PMNs, which release proteases and other granular proteins, e.g., elastase, myeloperoxidase and protein-arginine deiminase type 4. One specific effect related to PMNs is the generation of NETs, which are large, extracellular, web-like structures consisting of cytosolic and granule proteins with a scaffold of decondensed chromatin in which the majority of the DNA originates from the nucleus (). NETs protect against infection but have also been associated with a number of other immunoregulatory events such as binding antimicrobial peptides and priming immune cells (). In addition to this, NETs promote thrombotic events, since they bind both TF () and FXIIa () thereby being able to trigger both the extrinsic pathway of coagulation as well as the contact system and consequently the intrinsic pathway of coagulation. NET formation has been suggested to be an important promotor of thrombosis in the lungs of COVID-19 patients where C5a has been proposed to elicit the release of these morphological structures (, ).
Platelets and Endothelial Cells
Increased platelet activation and platelet-monocyte aggregates were observed in COVID-19 patients but not in patients presenting a mild syndrome (). Platelet counts tend to increase in COVID-19 patients and not be consumed and decrease in number as in patients with thromboembolism. This observed difference, which speaks against that the thrombi found in the lungs in COVID-19 patients are the result of embolism with a major thrombus formed elsewhere such as in deep vein thrombosis (DVT). Instead, it has been observed that COVID-19 patients exhibit reduced procoagulant platelet responses (), but platelets are found in the thrombi formed in the lung capillaries either as a result of activated endothelial cells or NETs formation (). Endothelial cells are poorly infected by Cov-Sars-2 since these cells express a low number of ACE-2 molecules (), but generation of both C5a and BK by the nearby pneumocytes can initiate expression of TF on both endothelial cells ()and neutrophils (, ) thereby promoting local thrombus formation.
Ischemic Injury
Hypoxia is anticipated to occur, particularly in the lungs during COVID-19, where major parts of the small airways may be totally clogged with fibrin, platelet-rich thrombi, and cells [Figure 2; ()]. Ischemia is expected to be a mechanism that is involved in the injury mediated by the IIIS in COVID-19, considering the low oxygen saturation in these patients. Ischemia is a major stress to the cell, which can lead to changes in the composition and protein expression of the cell membrane (). Consequently, IIIS in contact with a cell subjected to hypoxia, can recognize the cell surface as foreign, causing a thromboinflammatory reaction and, by extension, ischemia/reperfusion injury-like damage and cell death. The ischemic cell has a distinctive phenotype compared to the native one, which leads to that IIIS recognition molecules of the complement and the KK systems target the cell as foreign (non-self). In ischemia/reperfusion injury, MBL () and MASP-2 () of the LP and innate IgM antibodies (, ) of the CP have been suspected to be involved in the IIIS activation that occurs.
The Renin-Angiotensin System (RAS)
Hypertension is linked to the renin-angiotensin system (RAS) and an increased risk for severe COVID-19 infection. The docking protein for SARS-CoV-2 on human cells is angiotensin converting enzyme (ACE)-2 of the angiotensinogen cascade system, which may destroy the function of this protein. ACE-1 inhibitors (common hypertensive drugs) block the cleavage of angiotensin I to angiotensin II. ACE-1 is a regulator of BK, making it feasible that inhibition of ACE-1 could aggravate the ARDS condition in COVID-19 patients by increasing the levels of active BK. Although in a meta study focusing on the effects of renin-angiotensin system (RAS) inhibitors on the RAS and the outcome of COVID-19, no support for this concept was found. However, since this study is based on several clinical trials that treat RAS inhibitors as a common group further studies are needed to elucidate this issue (, ).
Conceptual Mechanisms Inducing COVID-19-Triggered ARDS
SARS-CoV-2-infected and ischemic, damaged epithelial and endothelial cells can activate all the IIIS cascade systems in a joint thromboinflammatory reaction in the lungs (Figure 2). During the development of ARDS, SARS CoV-2 and damaged cells (SARS CoV-2-infected, apoptotic, necrotic cells) are potential targets for the recognition molecules of the blood cascade systems. C1q, MBL, and FXII are known to recognize apoptotic and necrotic cells that can trigger the CP and LP of complement ultimately leading to cleavage of C3/C5 into C3a/C5a and C3b/C5b. BK generated by the KK system activation can cause dry cough () and pulmonary inflammation with edema () by binding to BKR2. C3a and C5a bind to the anaphylatoxin receptors: C3aR, C5aR1, and C5aR2 and C5a is also able to activate endothelial cells in COVID-19 patients leading to von Willebrand Factor (vWF) and p-selectin exposure on the endothelial lining thereby contributing to the thrombotic phenotype (). Supporting the importance of the C5a/C5aR1 axis is that COVID-19 patients generate C5a as detected in pulmonary lavage in proportion to the severity of the disease and high expression of C5aR1 was found in blood and on pulmonary myeloid cells (). C5a also induces expression of BKR1, (which contrary to BKR2 is not constitutively expressed) and BK can then act via both BKR2 (expressed on both the pulmonary epithelium and endothelium) and after cleavage to desArg9-BK via BKR1 (–), which also elicits increased vascular permeability, PMN chemotaxis, and nerve end stimulation, amplifying all of the above-mentioned reactions. Thus, C3a, C5a, and BK combined have the potential to cause a local edema and pulmonary leukocyte infiltration/inflammation that increases the distance between epithelial and endothelial cells in the alveolae, thereby hindering oxygenation of the blood (Figure 2). The poor oxygenation can lead to further ischemia (as described above) that in turn leads to even more IIIS activation thereby creating a vicious circle. Local thrombosis in the vasculature of the lung induced by activated endothelial cells that bind MBL, and expose selectins, TF and vWF on their surfaces, further aggravates the hypoxia. Chemotaxis and activation of neutrophlic granulocytes also cause NET formation and FXII activation (, ). Taken together these phenomena are likely drivers of the endothelialitis, the thrombus formation and the increased vascular angiogenesis linked to COVID-19 patients ().
Activation of the IIIS in COVID-19-induced ARDS have many similarities to ARDS of other etiologies, e.g., as in sepsis but there are also large differences both regarding activation mechanisms and the focus of the inflammation. We have previously reported that the activation of the IIIS in COVID-19 mainly occurs via the KK system and the LP and CP of the complement system (). By contrast, in septic shock, it has been reported by others that the key steps of complement activation consist of first the AP followed by the CP (). One explanation of these discrepancies may be the specific pathophysiologic process in SARS-CoV-2 infection as compared with the diverse and heterogeneous microbiology in sepsis of different origin. Another important dissimilarity between COVID-19 and sepsis-induced ARDS is the focus and origin of inflammation. In COVID-19, ARDS originates from the lung, which is in contrast to sepsis-induced ARDS that is caused by a secondary systemic inflammatory response in a distant organ, unless the infection focus already is in the lung (, ). In the latter case, usually termed pulmonary ARDS, the lung is the driver of IIIS activation with the highest IIIS activation locally, while in the former, usually termed extrapulmonary ARDS, the lung is only secondarily affected and IIIS activation measured as activation products in the plasma is less dependent on the severity of ARDS.
In summary, we hypothesize that activation of the IIIS, either caused directly by SARS-CoV-2, or more likely by large quantities of activated and damaged cells resulting from viral infection and ischemia, is the pathophysiological mechanism of the thromboinflammatory reaction that triggers the ARDS linked to COVID-19.
Therapeutics
A number of investigators have suggested the complement and KK systems as targets for treating COVID-19 (). In addition to previously known treatment of IIIS activation via inhibition of the coagulation system (heparin, warfarin, direct-acting oral anticoagulants [DOAC], etc.), a large number of inhibitors have recently been developed to regulate the complement system. There are several licensed drugs that affect the components of the IIIS. Treatment of paroxysmal noctural hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and myasthenia gravis has been performed for a long time by inhibiting complement factor C5 (using the anti-C5 antibodies eculizumab and ravulizimab) with excellent results (–). Also, several other anti-complement drugs are being developed for use in, for example, treatment of COVID-19. Two of these AMY-101 and pegcatacoplan (both C3 inhibitors of the compstatin family) were recently tested and AMY-101 shown promising results with faster clinical recovery and a reduction in a number of inflammatory parameters such as plasma levels of IL-6 (). In addition, the LP inhibitor narsoplimab (anti-MASP-2) has been tested in a small number of patients ().
Inhibition of the KK system appears to be a possible step in the search for therapeutic alternatives for treatment of COVID-19. In support of this hypothesis are several publications including the successful treatment of ARDS with icatibant in hantavirus infection (). The latter indicates that this may be a route of success, since it confirms that a BKR2 antagonist alleviated other types of virus-induced ARDS. Several currently registered drugs in clinical use for the treatment of angioedema target the KK system, which include icantibant, the kallikrein inhibitors lanadelumab (monoclonal antibody) and ecallantide (small molecular inhibitor), which is licensed in the USA. Also, C1-INH (both recombinant and in purified form), which inhibits both the complement and the KK systems, are examples of pharmaceuticals with a potential use to control IIIS activation in, e.g., COVID-19 patients. In a case control study C1-INH was investigated and shown to be safe and have some clinical effect (). In a case study without controls (92) with recombinant C1-INH (conestat alfa) the drug was well taken but the study was indecisive. Considering reports of very high concentrations of C1-INH in COVID-19 patients, this finding may explain this result (, 92).
In summary, all IIIS drugs were promising and had the expected effect on the targeted IIIS components and provided evidence that they affected thromboinflammation induced by IIIS to a varying degree. However, most of the studies included few patients without controls, which made evaluation of the results difficult. Further randomized and controlled studies will give us a deeper insight into the effect of these drugs alone. However, reflecting on the content of this review, combinations of IIIS inhibitors are most likely to be needed to get an optimal effect on COVID-19 ARDS. All trials currently registered in ClinicalTrials.gov testing IIIS-targeted components in COVID-19 are summarized in Table 1.
Table 1
| Drug (target) | Identifier | Participants | Study design | Last update |
|---|---|---|---|---|
| Kallikrein | ||||
| lanadelumab (kallikrein) | NCT04422509 | 43 | Randomized vs SOC | Nov 16, 2021 |
| lanadelumab (kallikrein) | NCT04460105 | 0 | Randomized vs placebo | Oct 20, 2020 |
| ISIS 721744 (kallikrein antisense) | NCT04549922 | 111 | Randomized vs placebo | April 19, 2021 |
| Icatibant | ||||
| C1-INH ± icatibant | NCT05010876 | 44 | Randomized vs SOC | Aug 18, 2021 |
| Iactibant | NCT04978051 | 120 | Randomized vs SOC | July 27, 2021 |
| C1-INH | ||||
| Conestat alfa (recomb C1-INH) | NCT04414631 | 80 | Randomized vs SOC | Nov 9, 2021 |
| Ruconest (recomb C1-INH) | NCT04705831 | 40 | Randomized vs SOC, crossover | Jan 12, 2021 |
| Ruconest (recomb C1-INH) | NCT04530136 | 120 | Randomized vs SOC | Dec 10, 2020 |
| C5 cleavage inhibitors | ||||
| Eculizumab | NCT04346797 | 120 | Randomized vs SOC | April 20, 2020 |
| Eculizumab | NCT04288713 | no info | no info found | March 20, 2020 |
| Ravulizumab | NCT04390464 | 1167 (3 arms) | Randomized vs SOC | May 18, 2020 |
| Ravulizumab | NCT04570397 | 32 | Randomized vs SOC | Jan 14, 2021 |
| Ravulizumab | NCT04369469 | 120 | Randomized vs SOC | Sept 22, 2021 |
| Zilucoplan (C5 cleavage inhibiting peptide) | NCT04382755 | 81 | Randomized vs SOC + antibiotics | July 2, 2021 |
| Zilucoplan (C5 cleavage inhibiting peptide) | NCT04590586 | 516 (7 arms) | Randomized vs SOC + placebo | Nov 23, 2021 |
| C3 cleavage inhibitors | ||||
| AMY-101 | NCT04395456 | 144 | Randomized vs placebo | Feb 20, 2021 |
| APL-9 | NCT04402060 | 65 | Randomized vs placebo | Sept 1, 2021 |
| Lectin pathway inhibitor | ||||
| Narsoplimab (anti MASP-2) | NCT04488081 | 1500 (8 arms) | Randomized | July 21, 2021 |
| + Remdesivir (anti CD14) | ||||
| C5aR antagonists | ||||
| avdoralimab (anti C5aR mAb) | NCT04371367 | 208 | Randomized vs placebo | May 27, 2021 |
| avdoralimab (anti C5aR mAb) | NCT04333914 | 219 | Randomized vs SOC | Aug 5, 2021 |
| vilobelimab (anti C5a mAb) | NCT04333420 | 390 | Randomized vs SOC + placebo | Dec 31, 2021 |
All trials currently (2022-01-28) registered in ClinicalTrials.gov testing targeting IIIS components in COVID-19.
SOC, standard of care.
Funding
The study was funded by the Swedish Research Council grants 2016-01060, 2016-04519, 2020-05762, 2021-02252, the Swedish Heart-Lung Foundation grant HLF 2020-0398 and by faculty grants from the Linnaeus University.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
BN and KE have written and edited the major part of the review. OE, KF, and MH-L have contributed to the writing and editing of the article. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Abbreviations
ACE, angiotensin converting enzyme; aHUS, atypical hemolytic uremic syndrome; AP, alternative pathway of complement; ARDS, acute respiratory distress syndrome; BK, bradykinin; BKR1/2, bradykinin receptor 1/2; C1-INH, C1 inhibitor; CAC, COVID-19-associated coagulopathy; CP, classical pathway of complement; CT, computed tomography; DAMPs, damage-associated molecular patterns; DIC, disseminated intravascular coagulation; DOAC, direct-acting oral anticoagulants; DVT, deep vein thrombosis; FXII, Factor XII; ICU, intensive care unit; HMWK, high molecular weight kininogen; IIIS, intravascular innate immune system; KK, kallikrein/kinin system; LMWH, low-molecular-weight heparin; LP, lectin pathway of complement; MERS, middle East respiratory syndrome; NETs, neutrophil extracellular traps; PAMPs, pathogen-associated molecular patterns; PMNs, polymorphonuclear leukocytes; PNH, paroxysmal noctural hemoglobinuria; RAS, renin-angiotensin system; SARS-1, severe acute respiratory ryndrome-1; TF, tissue factor; tPA, tissue plasminogen activator; vWF, von Willebrand factor.
References
1
LipcseyMPerssonBErikssonOBlomAMFromellKHultströmMet al. The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System. Front Immunol (2021) 12:627579. doi: 10.3389/fimmu.2021.627579
2
EkdahlKNTeramuraYHamadOAAsifSDuehrkopCFromellKet al. Dangerous Liaisons: Complement, Coagulation, and Kallikrein/Kinin Cross-Talk Act as a Linchpin in the Events Leading to Thromboinflammation. Immunol Rev (2016) 274(1):245–69. doi: 10.1111/imr.12471
3
EkdahlKNHongJHamadOALarssonRNilssonB. Evaluation of the Blood Compatibility of Materials, Cells, and Tissues: Basic Concepts, Test Models, and Practival Guidelines. Adv Exp Med Biol (2013) 735:257–70. doi: 10.1007/978-1-4614-4118-2_18
4
HowardMFarrarCASacksSH. Structural and Functional Diversity of Collectins and Ficolins and Their Relationship to Disease. Semin Immunopathol (2018) 40:75–85. doi: 10.1007/s00281-017-0642-0
5
RicklinDMastellosDCLambrisJD. Therapeutic Targeting of the Complement System. Nat Rev Drug Discovery (2019) 9:1–1. doi: 10.1038/s41573-019-0055-y
6
Tissue Factor (2022). Available at: https://www.proteinatlas.org/ENSG00000117525-F3/tissue (Accessed January 27, 2022).
7
KaplanAPGhebrehiwetB. The Plasma Bradykinin-Forming Pathways and its Interrelationships With Complement. Mol Immunol (2010) 47:2161–9. doi: 10.1016/j.molimm.2010.05.010
8
HessRWujakLHesseCSewaldKJonigkDWarneckeGet al. Coagulation Factor XII Regulates Inflammatory Responses in Human Lungs. Thromb Haemostasis (2017) 117:1896–907. doi: 10.1160/th16-12-0904
9
WilbsJKongX-DMiddendorpSJPrinceRCookeADemarestCTet al. Cyclic Peptide FXII Inhibitor Provides Safe Anticoagulation in a Thrombosis Model and in Artificial Lungs. Nat Commun (2020) 11:3890. doi: 10.1038/s41467-020-17648-w
10
MaasC. Plasminflammation-An Emerging Pathway to Bradykinin Production. Front Immunol (2019) 10:2046. doi: 10.3389/fimmu.2019.02046
11
BroughtonGJanisJEAttingerCE. The Basic Science of Wound Healing. Plast Reconstr Surg (2006) 117:12S–34S. doi: 10.1097/01.prs.0000225430.42531.c2
12
van DamLFKroftLJMvan der WalLICannegieterSCEikenboomJde JongeEet al. Clinical and Computed Tomography Characteristics of COVID-19 Associated Acute Pulmonary Embolism: A Different Phenotype of Thrombotic Disease? Thromb Res (2020) 193:86–9. doi: 10.1016/j.thromres.2020.06.010
13
MariettaMColuccioVLuppiM. COVID-19, Coagulopathy and Venous Thromboembolism: More Questions Than Answers. Intern Emerg Med (2020) 15(8):1375–87. doi: 10.1007/s11739-020-02432-x
14
StattinKLipcseyMAnderssonHPonténEAnderbergSBGradinAet al. Inadequate Prophylactic Effect of Low-Molecular Weight Heparin in Critically Ill COVID-19 Patients. J Crit Care (2020) 60:249–52. doi: 10.1016/j.jcrc.2020.08.026
15
AckermannMVerledenSEKuehnelMHaverichAWelteTLaengerFet al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. New Engl J Med (2020) 383:120–8. doi: 10.1056/nejmoa2015432
16
ZeidlerAKarpinskiTM. SARS-CoV, MERS-CoV, SARS-CoV-2 Comparison of Three Emerging Coronaviruses. Jundishapur J Microb (2020) 13(6):e103744. doi: 10.5812/jjm.103744
17
SkevakiCFragkouPCChengCXieMRenzH. Laboratory Characteristics of Patients Infected With the Novel SARS-CoV-2 Virus. J Infection (2020) 81:205–12. doi: 10.1016/j.jinf.2020.06.039
18
CavagnaEMuratoreFFerrariF. Pulmonary Thromboembolism in COVID-19: Venous Thromboembolism or Arterial Thrombosis? Radiol Cardiothorac Imaging (2020) 2:e200289. doi: 10.1148/ryct.2020200289
19
MackmanNAntoniakSWolbergASKasthuriRKeyNS. Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses. Arterioscler Thromb Vasc Biol (2020) 40(9):2033–44. doi: 10.1161/atvbaha.120.314514
20
SzekelyLBozokyBBendekMOstadMLavignassePHaagLet al. Pulmonary Stromal Expansion and Intra-Alveolar Coagulation are Primary Causes of COVID-19 Death. Heliyon (2021) 7:e07134. doi: 10.1016/j.heliyon.2021.e07134
21
AzkurAKAkdisMAzkurDSokolowskaMVeenWBrüggenMet al. Immune Response to SARS-CoV-2 and Mechanisms of Immunopathological Changes in COVID-19. Allergy (2020) 75:1564–81. doi: 10.1111/all.14364
22
StassiCMondelloCBaldinoGCardiaLAsmundoASpagnoloEV. An Insight Into the Role of Postmortem Immunohistochemistry in the Comprehension of the Inflammatory Pathophysiology of COVID-19 Disease and Vaccine-Related Thrombotic Adverse Events: A Narrative Review. Int J Mol Sci (2021) 22:12024. doi: 10.3390/ijms222112024
23
ReuschNDomenicoEDBonaguroLSchulte-SchreppingJBaßlerKSchultzeJLet al. Neutrophils in COVID-19. Front Immunol (2021) 12:652470. doi: 10.3389/fimmu.2021.652470
24
MacorPDuriguttoPMangognaABussaniRD’ErricoSZanonMet al. Multi-Organ Complement Deposition in COVID-19 Patients. Biomedicines (2021) 9:1003. doi: 10.3390/biomedicines9081003
25
MagroCMulveyJJBerlinDNuovoGSalvatoreSHarpJet al. Complement Associated Microvascular Injury and Thrombosis in the Pathogenesis of Severe COVID-19 Infection: A Report of Five Cases. Transl Res J Lab Clin Med (2020) 220:1–13. doi: 10.1016/j.trsl.2020.04.007
26
NorisMBenigniARemuzziG. The Case of Complement Activation in COVID-19 Multiorgan Impact. Kidney Int (2020) 98:314–22. doi: 10.1016/j.kint.2020.05.013
27
LutherTBülow-AnderbergSLarssonARubertssonSLipcseyMFrithiofRet al. COVID-19 Patients in Intensive Care Develop Predominantly Oliguric Acute Kidney Injury. Acta Anaesth Scand (2021) 65:364–72. doi: 10.1111/aas.13746
28
VirhammarJNääsAFällmarDCunninghamJLKlangAAshtonNJet al. Biomarkers for Central Nervous System Injury in Cerebrospinal Fluid are Elevated in COVID-19 and Associated With Neurological Symptoms and Disease Severity. Eur J Neurol (2021) 28:3324–31. doi: 10.1111/ene.14703
29
GuptaAMadhavanMVSehgalKNairNMahajanSSehrawatTSet al. Extrapulmonary Manifestations of COVID-19. Nat Med (2020) 26:1017–32. doi: 10.1038/s41591-020-0968-3
30
RosénJNorelandMStattinKLipcseyMFrithiofRMalinovschiAet al. Group UICC-19 R. ECG Pathology and its Association With Death in Critically Ill COVID-19 Patients, a Cohort Study. PloS One (2021) 16:e0261315. doi: 10.1371/journal.pone.0261315
31
Ferrer-GómezAPian-AriasHCarretero-BarrioINavarro-CanteroAPestañaDde PabloRet al. Late Cardiac Pathology in Severe Covid-19. A Postmortem Series of 30 Patients. Front Cardiovasc Med (2021) 8:748396. doi: 10.3389/fcvm.2021.748396
32
PfisterFVonbrunnERiesTJäckH-MÜberlaKLochnitGet al. Complement Activation in Kidneys of Patients With COVID-19. Front Immunol (2021) 11:594849. doi: 10.3389/fimmu.2020.594849
33
VirhammarJKumlienEFällmarDFrithiofRJackmannSSköldMKet al. Acute Necrotizing Encephalopathy With SARS-CoV-2 RNA Confirmed in Cerebrospinal Fluid. Neurology (2020) 95:445–9. doi: 10.1212/wnl.0000000000010250
34
FrithiofRRostamiEKumlienEVirhammarJFällmarDHultströmMet al. Critical Illness Polyneuropathy, Myopathy and Neuronal Biomarkers in COVID-19 Patients: A Prospective Study. Clin Neurophysiol Off J Int Fed Clin Neurophysiol (2021) 132:1733–40. doi: 10.1016/j.clinph.2021.03.016
35
WallinEHultströmMLipcseyMFrithiofRRubertssonSLarssonI-M. Intensive Care-Treated COVID-19 Patients’ Perception of Their Illness and Remaining Symptoms. Acta Anaesth Scand (2022) 66:240–7. doi: 10.1111/aas.13992
36
CharchafliehJWeiJLabazeGHouYJBabarshBStutzHet al. The Role of Complement System in Septic Shock. Clin Dev Immunol (2012) 2012:407324. doi: 10.1155/2012/407324
37
AidMBusman-SahayKVidalSJMaligaZBondocSStarkeCet al. Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. Cell (2020) 183:1354–1366.e13. doi: 10.1016/j.cell.2020.10.005
38
ErikssonOPerssonBLipcseyMEkdahlKNilssonB. Mannose-Binding Lectin is Associated With Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. Thromb Haemostasis (2020) 120(12):1720–4. doi: 10.1055/s-0040-1715835
39
IpWKEChanKHLawHKWTsoGHWKongEKPWongWHSet al. Mannose-Binding Lectin in Severe Acute Respiratory Syndrome Coronavirus Infection. J Infect Dis (2005) 191:1697–704. doi: 10.1086/429631
40
SkendrosPMitsiosAChrysanthopoulouAMastellosDCMetallidisSRafailidisPet al. Complement and Tissue Factor-Enriched Neutrophil Extracellular Traps are Key Drivers in COVID-19 Immunothrombosis. J Clin Invest (2020) 130(11):6151–7. doi: 10.1172/jci141374
41
EpsteinFHGabayCKushnerI. Acute-Phase Proteins and Other Systemic Responses to Inflammation. New Engl J Med (1999) 340:448–54. doi: 10.1056/nejm199902113400607
42
WangRXiaoHGuoRLiYShenB. The Role of C5a in Acute Lung Injury Induced by Highly Pathogenic Viral Infections. Emerg Microbes Infect (2019) 4:1–7. doi: 10.1038/emi.2015.28
43
SavittAGManimalaSWhiteTFandarosMYinWDuanHet al. SARS-CoV-2 Exacerbates COVID-19 Pathology Through Activation of the Complement and Kinin Systems. Front Immunol (2021) 12:767347. doi: 10.3389/fimmu.2021.767347
44
AliYMFerrariMLynchNJYaseenSDudlerTGragerovSet al. Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins. Front Immunol (2021) 12:714511. doi: 10.3389/fimmu.2021.714511
45
StravalaciMPaganiIParaboschiEPedottiMDoniAScavelloFet al. Recognition and Inhibition of SARS-CoV-2 by Humoral Innate Immunity Pattern Recognition Molecules. Nat Immunol (2022) 23(2):275–86. doi: 10.1038/s41590-021-01114-w.
46
BrosnahanSBJonkmanAHKuglerMCMungerJSKaufmanDA. COVID-19 and Respiratory System Disorders: Current Knowledge, Future Clinical and Translational Research Questions. Arterioscler Thromb Vasc Biol (2020) 40:2586–97. doi: 10.1161/atvbaha.120.314515
47
CugnoMMeroniPLGualtierottiRGriffiniSGrovettiETorriAet al. Complement Activation and Endothelial Perturbation Parallel COVID-19 Severity and Activity. J Autoimmun (2021) 116:102560. doi: 10.1016/j.jaut.2020.102560
48
JavaAApicelliAJLiszewskiMKColer-ReillyAAtkinsonJPKimAHJet al. The Complement System in COVID-19: Friend and Foe? JCI Insight (2020) 5(15):e140711. doi: 10.1172/jci.insight.140711
49
LoMWKemperCWoodruffTM. COVID-19: Complement, Coagulation, and Collateral Damage. J Immunol (2022) 205(6):1488–90. doi: 10.4049/jimmunol.2000644
50
RisitanoAMMastellosDCHuber-LangMYancopoulouDGarlandaCCiceriFet al. Complement as a Target in COVID-19? Nat Rev Immunol (2020) 20:343–4. doi: 10.1038/s41577-020-0320-7
51
TomoSKumarKPRoyDSankanagoudarSPurohitPYadavDet al. Complement Activation and Coagulopathy - an Ominous Duo in COVID19. Expert Rev Hematol (2021) 14:1–19. doi: 10.1080/17474086.2021.1875813
52
HolterJCPischkeSEdeBELindAJenumSHoltenARet al. Systemic Complement Activation is Associated With Respiratory Failure in COVID-19 Hospitalized Patients. Proc Natl Acad Sci (2020) 117:25018–25. doi: 10.1073/pnas.2010540117
53
CugnoMMeroniPLGualtierottiRGriffiniSGrovettiETorriAet al. COMPLEMENT ACTIVATION IN PATIENTS WITH COVID-19: A NOVEL THERAPEUTIC TARGET. J Allergy Clin Immunol (2020) 146:215–7. doi: 10.1016/j.jaci.2020.05.006
54
MaLSahuSKCanoMKuppuswamyVBajwaJMcPhatterJet al. Increased Complement Activation is a Distinctive Feature of Severe SARS-CoV-2 Infection. Sci Immunol (2021) 6:eabh2259. doi: 10.1126/sciimmunol.abh2259
55
YanBFreiwaldTChaussDWangLWestEMirabelliCet al. SARS-CoV-2 Drives JAK1/2-Dependent Local Complement Hyperactivation. Sci Immunol (2021) 6:eabg0833. doi: 10.1126/sciimmunol.abg0833
56
BrasenCLChristensenHOlsenDAKahnsSAndersenRFMadsenJBet al. Daily Monitoring of Viral Load Measured as SARS-CoV-2 Antigen and RNA in Blood, IL-6, CRP and Complement C3d Predicts Outcome in Patients Hospitalized With COVID-19. Clin Chem Lab Med Cclm (2021) 0:000010151520210694. doi: 10.1515/cclm-2021-0694
57
ColarussoCTerlizziMPintoASorrentinoR. A Lesson From a Saboteur: High Molecular Weight Kininogen (HMWK) Impact in COVID-19. Brit J Pharmacol (2020) 177(21):4866–72. doi: 10.1111/bph.15154
58
GarvinMRAlvarezCMillerJIPratesETWalkerAMAmosBKet al. A Mechanistic Model and Therapeutic Interventions for COVID-19 Involving a RAS-Mediated Bradykinin Storm. Elife (2020) 9:e59177. doi: 10.7554/elife.59177
59
MaglakelidzeNMantoKMCraigTJ. A Review: Does Complement or the Contact System Have a Role in Protection or Pathogenesis of COVID-19? Pulm Ther (2020) 6(2):169–76. doi: 10.1007/s41030-020-00118-5
60
BuschMHTimmermansSAMEGNagyMVisserMHuckriedeJAendekerkJPet al. Neutrophils and Contact Activation of Coagulation as Potential Drivers of COVID-19. Circulation (2020) 142:1787–90. doi: 10.1161/circulationaha.120.050656
61
ZhouFYuTDuRFanGLiuYLiuZet al. Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet (2020) 395:1054–62. doi: 10.1016/s0140-6736(20)30566-3
62
PapayannopoulosV. Neutrophil Extracellular Traps in Immunity and Disease. Nat Rev Immunol (2018) 18:134–47. doi: 10.1038/nri.2017.105
63
OehmckeSMörgelinMHerwaldH. Activation of the Human Contact System on Neutrophil Extracellular Traps. J Innate Immun (2009) 1:225–30. doi: 10.1159/000203700
64
HottzEDAzevedo-QuintanilhaIGPalhinhaLTeixeiraLBarretoEAPãoCRRet al. Platelet Activation and Platelet-Monocyte Aggregate Formation Trigger Tissue Factor Expression in Patients With Severe COVID-19. Blood (2020) 136:1330–41. doi: 10.1182/blood.2020007252
65
DenormeFManneBKPortierIPetreyACMiddletonEKileBTet al. COVID-19 Patients Exhibit Reduced Procoagulant Platelet Responses. J Thromb Haemost (2020) 18(11):3067–73. doi: 10.1111/jth.15107
66
LiuFHanKBlairRKenstKQinZUpcinBet al. SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro. Front Cell Infect Mi (2021) 11:701278. doi: 10.3389/fcimb.2021.701278
67
IkedaKNagasawaKHoriuchiTTsuruTNishizakaHNihoY. C5a Induces Tissue Factor Activity on Endothelial Cells. Thromb Haemostasis (1997) 77:394 398. doi: 10.1055/s-0038-1655974
68
RitisKDoumasMMastellosDMicheliAGiaglisSMagottiPet al. Lambris JD. A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways. J Immunol (2006) 177:4794–802. doi: 10.4049/jimmunol.177.7.4794
69
van der PolPSchlagweinNvan GijlswijkDJBergerSPRoosABajemaIMet al. Mannan-Binding Lectin Mediates Renal Ischemia/Reperfusion Injury Independent of Complement Activation: MBL Is Cytotoxic to Tubular Epithelial Cells. Am J Transplant (2012) 12:877–87. doi: 10.1111/j.1600-6143.2011.03887.x
70
ZhangMHouYJCavusogluELeeDCSteffensenRYangLet al. MASP-2 Activation is Involved in Ischemia-Related Necrotic Myocardial Injury in Humans. Int J Cardiol (2013) 166:499 504. doi: 10.1016/j.ijcard.2011.11.032
71
ZhangMAlicotEMCarrollMC. Human Natural IgM can Induce Ischemia/Reperfusion Injury in a Murine Intestinal Model. Mol Immunol (2008) 45:4036–9. doi: 10.1016/j.molimm.2008.06.013
72
van der PolPRoosABergerSPDahaMRvan KootenC. Natural IgM Antibodies are Involved in the Activation of Complement by Hypoxic Human Tubular Cells. Am J Physiol-renal (2011) 300:F932 40. doi: 10.1152/ajprenal.00509.2010
73
ChungMKKarnikSSaefJBergmannCBarnardJLedermanMMet al. SARS-CoV-2 and ACE2: The Biology and Clinical Data Settling the ARB and ACEI Controversy. Ebiomedicine (2020) 58:102907. doi: 10.1016/j.ebiom.2020.102907
74
HewittMMAdamsGMazzoneSBMoriNYuLCanningBJ. Pharmacology of Bradykinin-Evoked Coughing in Guinea Pigs. J Pharmacol Exp Ther (2016) 357:620–8. doi: 10.1124/jpet.115.230383
75
OstenfeldSBygumARasmussenER. Life-Threatening ACE Inhibitor-Induced Angio-Oedema Successfully Treated With Icatibant: A Bradykinin Receptor Antagonist. BMJ Case Rep (2015) 2015):bcr2015212891. doi: 10.1136/bcr-2015-212891
76
AielloSGastoldiSGalbuseraMRuggenentiPLPortalupiVRotaSet al. C5a and C5aR1 are Key Drivers of Microvascular Platelet Aggregation in Clinical Entities Spanning From aHUS to COVID-19. Blood Adv (2022) 6(3):866–81. doi: 10.1182/bloodadvances.2021005246
77
CarvelliJDemariaOVélyFBatistaLBenmansourNCFaresJet al. Association of COVID-19 Inflammation With Activation of the C5a-C5aR1 Axis. Nature (2020) 588(7836):146–50. doi: 10.1038/s41586-020-2600-6
78
KaplanAPJosephK. Pathogenic Mechanisms of Bradykinin Mediated Diseases: Dysregulation of an Innate Inflammatory Pathway. Adv Immunol (2014) 121:41 89. doi: 10.1016/b978-0-12-800100-4.00002-7
79
MugishoOORobilliardLDNicholsonLFBGrahamESO’CarrollSJ. Bradykinin Receptor-1 Activation Induces Inflammation and Increases the Permeability of Human Brain Microvascular Endothelial Cells. Cell Biol Int (2020) 44:343–51. doi: 10.1002/cbin.11232
80
TerzuoliECortiFNannelliGGiachettiADonniniSZicheM. Bradykinin B2 Receptor Contributes to Inflammatory Responses in Human Endothelial Cells by the Transactivation of the Fibroblast Growth Factor Receptor FGFR-1. Int J Mol Sci (2018) 19:2638. doi: 10.3390/ijms19092638
81
RennéTStavrouEX. Roles of Factor XII in Innate Immunity. Front Immunol (2019) 10:2011. doi: 10.3389/fimmu.2019.02011
82
PelosiPD’OnofrioDChiumelloDPaoloSChiaraGCapelozziVLet al. Pulmonary and Extrapulmonary Acute Respiratory Distress Syndrome are Different. Eur Respir J (2003) 22:48s–56s. doi: 10.1183/09031936.03.00420803
83
GibsonPGQinLPuahSH. COVID-19 Acute Respiratory Distress Syndrome (ARDS): Clinical Features and Differences From Typical Pre-COVID-19 ARDS. Med J Aust (2020) 213:54. doi: 10.5694/mja2.50674
84
CampbellCMKahwashR. Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis? Circulation (2020) 141:1739–41. doi: 10.1161/circulationaha.120.047419
85
DiurnoFNumisFGPortaGCirilloFMaddalunoSRagozzinoAet al. Eculizumab Treatment in Patients With COVID-19: Preliminary Results From Real Life ASL Napoli 2 Nord Experience. Eur Rev Med Pharmaco (2020) 24:4040–7. doi: 10.26355/eurrev_202004_20875
86
GiudiceVPaglianoPVatrellaAMasulloAPotoSPolverinoBMet al. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study. Front Pharmacol (2020) 11:857. doi: 10.3389/fphar.2020.00857
87
LaurenceJMulveyJJSeshadriMRacanelliAHarpJSchenckEJet al. Anti-Complement C5 Therapy With Eculizumab in Three Cases of Critical COVID-19. Clin Immunol Orlando Fla (2020) 219:108555. doi: 10.1016/j.clim.2020.108555
88
MastaglioSRuggeriARisitanoAMAngelilloPYancopoulouDMastellosDCet al. The First Case of COVID-19 Treated With the Complement C3 Inhibitor AMY-101. Clin Immunol (2020) 215:108450. doi: 10.1016/j.clim.2020.108450
89
RambaldiAGrittiGMicòMCFrigeniMBorleriGSalviAet al. Endothelial Injury and Thrombotic Microangiopathy in COVID-19: Treatment With the Lectin-Pathway Inhibitor Narsoplimab. Immunobiology (2020) 225:152001. doi: 10.1016/j.imbio.2020.152001
90
LaineOLeppänenIKoskelaSAntonenJMäkeläSSinisaloMet al. Severe Puumala Virus Infection in a Patient With a Lymphoproliferative Disease Treated With Icatibant. Infect Dis (2014) 47:107–11. doi: 10.3109/00365548.2014.969304
91
MansourEPalmaACUlafRGRibeiroLCBernardesAFNunesTAet al. Safety and Outcomes Associated With the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19. Viruses (2021) 13:309. doi: 10.3390/v13020309
92
UrwylerPMoserSCharitosPHeijnenIAFMRudinMSommerGet al. Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System. Front Immunol (2020) 11:2072. doi: 10.3389/fimmu.2020.02072
Summary
Keywords
cascade system, leukocytes, platelets, plasma proteins, COVID-19
Citation
Nilsson B, Persson B, Eriksson O, Fromell K, Hultström M, Frithiof R, Lipcsey M, Huber-Lang M and Ekdahl KN (2022) How the Innate Immune System of the Blood Contributes to Systemic Pathology in COVID-19-Induced ARDS and Provides Potential Targets for Treatment. Front. Immunol. 13:840137. doi: 10.3389/fimmu.2022.840137
Received
20 December 2021
Accepted
14 February 2022
Published
08 March 2022
Volume
13 - 2022
Edited by
Zoltán Prohászka, Semmelweis University, Hungary
Reviewed by
Marina Noris, Mario Negri Pharmacological Research Institute (IRCCS), Italy; Daniel Ricklin, University of Basel, Switzerland; Christian Drouet, U1016 Institut Cochin (INSERM), France
Updates
Copyright
© 2022 Nilsson, Persson, Eriksson, Fromell, Hultström, Frithiof, Lipcsey, Huber-Lang and Ekdahl.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bo Nilsson, bo.nilsson@igp.uu.se
This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.